The world’s largest manufacturer of contrast agents for gastrointestinal radiology has taken a 5% equity position in PointDx, an emerging medical technology company focused on the development of virtual colonoscopy software and structured reporting solutions for radiology. The deal also provides E-Z-EM with a three-year warrant to purchase an additional 120,000 shares and one seat on the PointDx board of directors. By taking an equity stake in PointDx, E-Z-EM hopes to follow and support the development of new applications in GI medicine.
